GlassScriptPhysician profile
Christa E Mccoll
NPI 1821701012
$3,734.25
in general payments reported to CMS, 2019-2025
31 companies · $581 in 2025
The $581 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $35.25 · 2023: $2,159 · 2024: $959 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,400 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,400.33 |
| Education | $298.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $484.38 | 2023-2024 | Lokelma, Farxiga |
| Mallinckrodt Hospital Products INC. | $369.80 | 2023-2024 | Acthar, Terlivaz |
| Ardelyx, INC. | $331.09 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Otsuka America Pharmaceutical, INC. | $273.37 | 2023-2025 | Jynarque |
| Amgen INC. | $272.45 | 2023-2025 | Krystexxa, Tavneos |
| Vifor Pharma, INC. | $259.24 | 2023-2024 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $244.08 | 2023-2025 | |
| Travere Therapeutics, INC. | $208.37 | 2023-2024 | |
| Calliditas Therapeutics US INC. | $183.83 | 2023-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $147.23 | 2023 | Rayaldee |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $108.91 | 2024 | |
| Horizon Therapeutics Plc | $105.15 | 2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $97.13 | 2023-2024 | Lupkynis |
| Novo Nordisk INC | $73.83 | 2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $61.76 | 2023-2024 | Jardiance |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $58.30 | 2023-2025 | Onpattro, Oxlumo, Givlaari |
| Kyowa Kirin, INC. | $52.04 | 2023-2024 | Crysvita |
| Fresenius USA Marketing, INC. | $48.46 | 2024-2025 | Velphoro |
| Novartis Pharmaceuticals Corporation | $44.62 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.03 | 2023-2024 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $39.08 | 2023 | |
| Medtronic, INC. | $35.25 | 2022 | |
| Ani Pharmaceuticals, INC. | $30.64 | 2023 | Purified Cortrophin Gel |
| Genentech USA, INC. | $30.49 | 2025 | Gazyva |
| Apellis Pharmaceuticals, INC. | $27.75 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.22 | 2023 | Gattex |
| Glaxosmithkline, LLC. | $19.04 | 2025 | Shingrix |
| Averitas Pharma INC. | $18.49 | 2024 | Qutenza |
| Cormedix INC. | $17.72 | 2025 | Defencath |
| Viiv Healthcare Company | $14.34 | 2023 | Rukobia |
| Pharmacosmos Therapeutics INC. | $13.16 | 2023 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christa Mccoll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.